SYGNIS AG signs supply agreement with US Biological for the Lightning-Link® antibody labelling technology

November 28th, 2017

Heidelberg, Germany and Cambridge, UK, 28 November 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology. Heikki Lanckriet, CEO and CSO of SYGNIS AG,…

View

AminTRAP HIS Prepacked Column

November 27th, 2017

View

Share your data and get 25% OFF your next order!

November 23rd, 2017

At Expedeon, we care about the quality of our products and the results produced from our products and services. That is why we are always grateful to receive any data from our valued customers. This way we can learn more about how our products are used and help more researchers. If you would like to share…

View

40nm Colloidal gold FREE Sample

November 23rd, 2017

    *T&Cs apply: Only applicable to free samples of 40nm gold nanoparticles. Free samples available for new customers of Expedeon’ colloidal gold only. Free samples are not available through distributors and re-sellers. Only one sample per person. Only while stocks last.

View

SYGNIS AG partners with Abingdon Health to provide full service custom lateral flow assay design and supply

November 7th, 2017

  Cambridge, UK, 07 November 2017: SYGNIS AG, under the Expedeon (Innova) brand name, a specialist provider of bioconjugation products and services, today announced it has established a partnership with Abingdon Health Ltd (“Abingdon”), which will enable Innova to provide its customers with full lateral flow assay development services as well as establishing Innova as…

View

Your preferred local currency is now